A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Stopped Terminated early dt to acquisition of Sponsor and change in corporate priorities
Conditions
- Pulmonary Arterial Hypertension
Interventions
- DRUG: AIR001 (sodium nitrite inhalation solution)
Sponsor
Aires Pharmaceuticals, Inc.